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Abstract 37 
 38 
Hypoxia-inducible factor (HIF) appears to function as a global master regulator of 39 
cellular and systemic responses to hypoxia. HIF-pathway manipulation is of therapeutic 40 
interest, however global, systemic upregulation of HIF may have as yet unknown effects 41 
on multiple processes. We utilized a mouse model of Chuvash polycythemia (CP), a rare 42 
genetic disorder which modestly increases expression of HIF target genes in normoxia, 43 
to understand what these effects might be within the heart. 44 
 45 
An integrated in and ex vivo approach was employed. In comparison to wild-type 46 
controls, CP mice had evidence (using in vivo MRI) of pulmonary hypertension, right 47 
ventricular hypertrophy, and increased left ventricular ejection fraction. Glycolytic flux 48 
(measured using 3H glucose) in the isolated, contracting, perfused CP heart was 1.8-fold 49 
higher. Net lactate efflux was 1.5-fold higher. Furthermore, in vivo 13C magnetic 50 
resonance spectroscopy (MRS) of hyperpolarized 13C1 pyruvate revealed a 2-fold 51 
increase in real-time flux through lactate dehydrogenase in the CP hearts, and a 1.6-fold 52 
increase through pyruvate dehydrogenase. 31P MRS of perfused CP hearts under 53 
increased workload (isoproterenol infusion) demonstrated increased depletion of 54 
phosphocreatine relative to ATP. Intriguingly, no changes in cardiac gene expression 55 
were detected. 56 
 57 
In summary, a modest systemic dysregulation of the HIF pathway resulted in clear 58 
alterations in cardiac metabolism and energetics. However, in contrast to studies 59 
generating high HIF levels within the heart, the CP mice showed neither the predicted 60 
changes in gene expression nor any degree of LV impairment. We conclude that the 61 
effects of manipulating HIF on the heart are dose-dependent. 62 
 63 
 64 
New and noteworthy 65 
 66 
This is the first integrative metabolic and functional study of the effects of modest HIF 67 
manipulation within the heart. Of particular note, the combination (and correlation) of 68 
perfused heart metabolic flux measurements with the new technique of real-time in vivo 69 
MR spectroscopy using hyperpolarized pyruvate is a novel development. 70 
 71 
 72 
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Introduction 77 
 78 
Prolonged hypoxia results in diverse changes within multiple organ systems - 79 
ventilatory acclimatization, increased erythropoiesis, pulmonary vascular remodeling, 80 
and metabolic alterations occur(54). Many of these diverse cellular and systemic 81 
responses to hypoxia are, or are likely to be, coordinated by the hypoxia-inducible factor 82 
(HIF) family of transcription factors. HIF is a heterodimer, comprising an oxygen-83 
regulated alpha subunit (HIF-1α, HIF-2α, or HIF-3α) and a ubiquitous beta subunit (HIF-84 
1β). The stability of HIF-α subunits is regulated by oxygen-dependent prolyl 85 
hydroxylation (by prolyl-4-hydroxylase domain proteins, PHDs) which enables 86 
recognition by the von Hippel-Lindau (VHL) ubiquitin E3 ligase and subsequent 87 
degradation via the ubiquitin-proteasome pathway(31, 54). Hence, HIF appears to 88 
function as a global master regulator of cellular and systemic responses to hypoxia in all 89 
metazoan species studied to date(36). 90 
 91 
There is considerable interest in understanding further the role of HIF in both individual 92 
organ systems and within integrative physiology, driven in part by the potential benefits 93 
of VHL-HIF pathway manipulation in the treatment of cancer and vascular disease(49). 94 
For example, global, systemic upregulation of HIF may have as yet unknown effects on 95 
multiple cellular and physiological processes. We sought to understand what these 96 
effects might be within the heart. 97 
 98 
Exposure of animals and humans to sustained hypoxia results in a consistent pattern of 99 
myocardial alterations in metabolic gene expression, substrate utilization, energetics, 100 
and function. The dynamic changes in gene expression increase the capacity for glucose 101 
uptake(63) and utilization(1, 62), whilst capacity for fatty acid utilization is 102 
reduced(62). Indeed, myocardial glucose uptake is increased in high-altitude 103 
natives(21) and in rats exposed to hypobaric hypoxia(28). These alterations in substrate 104 
utilization may affect myocardial energetics and function – lower phosphocreatine 105 
(PCr):ATP ratios were observed in Sherpa hearts(20), in lowlanders exposed to 20 106 
hours of normobaric hypoxia (with accompanying diastolic dysfunction)(22), and in 107 
trekkers travelling to Everest base camp at 5300 m (also with impaired diastolic 108 
function)(23). 109 
 110 
It is of note that the cardiac metabolic changes seen in response to hypoxia are similar to 111 
those observed in heart failure(34, 43-45). Indeed, it has been hypothesized that 112 
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myocardial hypoxia, with consequent activation of the HIF pathway, may play a role in 113 
altering cardiac substrate utilization, energetics and contractile function; these changes 114 
may then cause or exacerbate heart failure. This hypothesis has been explored in 115 
experiments producing very high levels of HIF in the heart, from which it is clear that 116 
major alterations in HIF give rise to metabolic changes and cardiomyopathy(7, 24, 29, 117 
35, 40, 41). However, these experiments do not reveal whether more modest alterations 118 
in HIF, particularly at a systemic level, produce similar results. 119 
 120 
Chuvash polycythemia (CP) is a rare autosomal recessive disorder with the potential to 121 
address this question. CP arises from a single point mutation in VHL which diminishes 122 
the binding affinity of the protein for hydroxylated HIF-1α and HIF-2α, increasing the 123 
expression of HIF target genes under normoxic conditions(2, 14). Patients with CP 124 
develop polycythemia, pulmonary hypertension, increased ventilatory and pulmonary 125 
vascular sensitivity to hypoxia, and altered skeletal muscle metabolism and 126 
energetics(14, 65), although any effects on cardiac function remain unidentified. Many 127 
aspects of the human disease have been shown to be faithfully recapitulated in the 128 
mouse model(18, 19, 39, 64).  129 
 130 
The CP mouse therefore provides a unique opportunity to study the effects on the heart 131 
of long term, systemic activation of the HIF pathway at more ‘physiological’ levels, 132 
without the confounding influence of periods of reduced oxygen availability through 133 
hypoxia. The purpose of the present study was to investigate the cardiac metabolic and 134 
functional phenotype of CP, utilizing both in- and ex-vivo techniques. 135 
  136 
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Methods 137 
Animals. CP breeding pairs were donated, and the original mutation was generated on a 138 
C57BL6 background as described previously(18). CP and wild type (homozygous, WT) 139 
mice (from the same breeding colony of mice heterozygous for the VHL Chuvash 140 
mutation) were used for all comparisons. All animal procedures were compliant with 141 
both the UK Home Office Animals (Scientific Procedures) Act 1986 and the Local Ethical 142 
Review Procedures (University of Oxford Medical Sciences Division Ethical Review 143 
Committee). Mice were housed within individually ventilated cages, in room air, with 144 
free access to food and water. 145 
 146 
Hematology and analysis of plasma metabolites. Following excision of the heart for 147 
perfusion, blood was collected immediately from the chest cavity. Hematocrits, in a 148 
heparinized capillary tube, were measured using a hematocrit centrifuge (Hettich, 149 
Germany); hemoglobin was measured using a HemoCue Hb 201+ (HemoCue, UK). The 150 
remaining blood was centrifuged at 4 °C and the plasma subsequently frozen in liquid 151 
nitrogen. All plasma analysis was performed on an ABX Pentra 400 Clinical Chemistry 152 
analyzer (Horiba ANX S.A.S, UK). 153 
 154 
Cardiac magnetic resonance imaging (MRI). Anesthesia was induced using 5%, and 155 
maintained with 1 – 2%, isoflurane in 100% O2. Respiratory rate and ECG were 156 
monitored continuously. Cine MRI was performed as described previously(58). Mice 157 
were placed in a purpose-built cradle, which was lowered into a vertical-bore 11.7 T 158 
(500 MHz) system (Magnex, UK) with a 40 mm birdcage coil (Bruker, Germany). A stack 159 
of contiguous, 1 mm thick, true short axis ECG- and respiration-gated cine/FLASH 160 
images were acquired to cover the entire heart. Image data were analyzed using the 161 
ImageJ software (NIH Image, USA). End-systole (ES) and end-diastole (ED) frames for 162 
each slice were identified and the LV endo- and epi-cardial borders outlined in all slices 163 
to give values for ESV (end-systolic volume) and EDV. Stroke volume (SV = EDV – ESV), 164 
ejection fraction (EF = (SV/EDV) x 100), and cardiac output (CO = SV x heart rate) were 165 
calculated. LV mass was calculated as the product of the LV volume and the specific 166 
gravity of myocardium (1.05 g/cm3). The mid-ventricular (MV) slice was defined as the 167 
one in which the papillary muscles were most prominent; right ventricle (RV) free wall 168 
thickness was measured in three separate locations in this slice, and subsequently 169 
averaged. 170 
 171 
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To quantify septal bowing (the distortion of the LV), a novel method was used. First, the 172 
LV epi-cardial border in early-diastole in the MV slice was outlined, giving an actual 173 
perimeter length (PA) and area (AA). The maximum possible area enclosed by a 174 
perimeter of any given length arises when the figure is a circle. For a perimeter of length 175 
PA, we denote this area as AC. If the LV were perfectly circular, then the ratio of AA to AC 176 
would be 1. As the LV becomes increasingly distorted in shape AA falls relative to AC, and 177 
hence the ratio will fall below 1. This ‘septal bowing ratio’ thus enables quantification of 178 
the distortion of the septum using the LV itself as the comparator. We chose to quantify 179 
septal bowing in this way, as it is an approach that is likely to be relatively insensitive to 180 
observer variability. We expect that a relatively linear relationship would exist between 181 
this index and other indices of septal bowing, such as the ratio between the long and 182 
short axes in a short-axis ventricular slice (as introduced by Ryan et al.(56), and which 183 
correlates with pulmonary artery pressure in patients with pulmonary hypertension), 184 
but this has not been tested directly. 185 
 186 
Gene expression (Real-Time PCR). Total RNA was extracted from 20 – 30 mg powdered 187 
(in liquid nitrogen) whole-heart tissue (following Langendorff perfusion) and whole-188 
lung tissue. Total RNA was extracted using the Rneasy Fibrous Kit (Qiagen, UK), 189 
including a Dnase treatment step, and complementary DNA immediately synthesized 190 
from 1 μg RNA using the Applied Biosystems High Capacity cDNA Reverse Transcription 191 
Kit (Life Technologies, UK). Real-Time PCR was performed using an ABI Prism 7000 192 
Sequence Detection System (Applied Biosystems, UK) with TaqMan Universal PCR 193 
Master Mix and TaqMan Gene Expression Assays (choosing manufacturer-194 
recommended assays: Applied Biosystems, UK). Relative quantification of mRNA 195 
expression levels was determined using the standard curve method and normalized to 196 
beta-actin (heart tissue) or 18s ribosomal RNA (lung tissue). 197 
 198 
Gene expression (Micro-array). Total RNA was extracted from 20 – 30 mg powdered (in 199 
liquid nitrogen) whole-heart tissue using the Rneasy Fibrous Kit (Qiagen, UK), including 200 
a Dnase treatment step. The RNA integrity was assessed on a BioAnalyzer (Agilent 201 
Laboratories, US); all samples had a RNA Integrity Number (RIN) ≥ 7. Labelled sense 202 
ssDNA for hybridisation was generated from 200 ng starting RNA with the Ambion WT 203 
expression kit (P/N 4411973) and the Affymetrix GeneChip WT Terminal Labeling and 204 
Controls Kit (P/N 901525) according to the manufacturer’s instructions. The 205 
distribution of fragmented sense ssDNA lengths was measured on the BioAnalyser. The 206 
fragmented ssDNA was labeled and hybridised for 17 hours at 45 °C to the Affymetrix 207 
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GeneChip Human Mouse 1.0 ST Array (Affymetrix). Chips were processed on an 208 
Affymetrix GeneChip Fluidics Station 450 and Scanner 3000. Affymetrix Command 209 
Console was used to generate cel files and Affymetrix Expression Console was used for 210 
the quality control. Arrays were RMA normalised in GeneSpring GX 12 and differentially 211 
expressed genes were identified using Limma with a Benjamini and Hochberg multiple 212 
testing correction of  ≤ 0.05.  As few genes were detected using this method the data 213 
were re-analysed using PLIER normalisation and a Student’s t-test with a p-value cut off 214 
of ≤ 0.05 and a fold change difference between wild type and Chuvash of  ≥ 1.3.   215 
 216 
 217 
Isolated heart perfusion. Mice were terminally anesthetized with an intraperitoneal 218 
injection of sodium pentobarbitol (500 mg/kg, Merial, UK) and the heart excised and 219 
arrested in ice-cold Krebs-Henseleit buffer; blood was immediately collected from the 220 
chest cavity for subsequent analysis. The ascending aorta was cannulated and the heart 221 
perfused retrograde in Langendorff mode at 37 °C at a constant perfusion pressure of 80 222 
mmHg. A polyethylene balloon, connected to a pressure transducer and used to measure 223 
cardiac function, was inserted into the left ventricle (LV) lumen and its volume adjusted 224 
to produce an end-diastolic pressure (EDP) of 4 – 8 mmHg. Rate pressure product (RPP) 225 
was calculated as the product of LV developed pressure (systolic pressure minus EDP) 226 
and heart rate. Hearts were perfused with 100 ml of a modified Krebs-Henseleit re-227 
circulating buffer (118 mmol/L NaCl, 3.7 mmol/L KCl, 1.2 mmol/L MgSO4, 1.97 mmol/L 228 
CaCl2, 0.5 mmol/L Na2EDTA, 25 mmol/L NaHCO3, 1.2 mmol/L KH2PO4) containing 11 229 
mmol/L glucose and 0.4 mmol/L palmitate pre-bound to 1.5 % albumin as substrates. 230 
The buffer was continually gassed with a mix of 95% O2 with 5 % CO2. 231 
 232 
Perfused heart energetics. Perfused hearts were inserted into an 11.7 T (500 MHz) 233 
vertical bore (123 mm internal diameter) magnet (Magnex Scientific, UK) with a 10 mm 234 
probe (Rapid, Germany) containing concentric 1H and 31P sensitive coils. Fully relaxed 235 
31P spectra were acquired using pulse-and-collect sequence at a repetition time of 10 s 236 
and a flip angle of 90° (32 averages, total acquisition time of 5 min, steady state. 237 
Approximate doubling of the RPP was then achieved by an infusion of isoproterenol 238 
(concentration received by the heart 2 – 5 nM) and further spectra acquired (minimum 239 
acquisition time 5 min). Spectra were analyzed using the jMRUI software(42) to give 240 
values for phosphocreatine (PCr) and γATP abundance, and the ratio of these two. 241 
Spectra for each perfusion condition (standard, or isoproterenol) were averaged to give 242 
final values for PCr:ATP. 243 
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 244 
Measurement of cardiac substrate metabolism. To determine glycolytic flux in the 245 
perfused heart, 50 μCi of D[5-3H]-glucose (Amersham, UK) were added to the re-246 
circulating buffer. Following a 10 min stabilization period, perfusate samples were 247 
collected at 5 min intervals for 35 min. 3H20 was separated from the D[5-3H]-glucose in 248 
the time samples using Dowex® ion exchange resin (Sigma, UK) and subsequently used 249 
to calculate the glycolytic rate. Due to the position of the 3H label, this method gives a 250 
measure of true glycolytic rate since the label is cleaved by enolase in the cytosol. 251 
 252 
Cardiac lactate efflux was determined by measuring lactate concentration 253 
spectrophotometrically in timed perfusate collections using lactate dehydrogenase. This 254 
method gives a measure of net lactate efflux from the heart. Cardiac palmitate oxidation 255 
rates were determined in a separate group of perfused hearts by adding 50 μCi of [9,10-256 
3H]-palmitate (Amersham, UK) to the re-circulating buffer and performing a chloroform-257 
methanol Folch extraction on the time buffer samples to collect the 3H20. 258 
 259 
Measurement of in vivo cardiac metabolism in real-time. Mice were studied in the early 260 
absorptive (fed) state, between 1 and 11 am. They were anesthetized in isoflurane and 261 
O2 and intravenous access was gained using a 32 G tail-vein cannula. Mice were then 262 
positioned within a 7 T horizontal-bore MR scanner. Respiratory rate and ECG were 263 
monitored continuously. As described previously(12), 0.15 ml of hyperpolarized 13C1 264 
pyruvate (0.48 mmol/kg) was injected over 10 s, followed by a 0.05 ml flush of 265 
heparinized saline to clear the delivery line. Sixty individual ECG-gated 13C MR cardiac 266 
spectra were acquired over 1 min following injection and subsequently analyzed using 267 
the AMARES algorithm in the jMRUI software package (Version 4.0(42)). The peak areas 268 
of 13C1 pyruvate, 13C1 lactate, 13C1 alanine and 13C1 bicarbonate at each time point were 269 
quantified and used as input data for a kinetic model as described previously(12). 270 
 271 
Statistical analysis. Differences between groups were assessed using one-way analysis of 272 
variance using SPSS Statistics 19 (IBM, USA). 273 
  274 
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Results 275 
The purpose of this study was to determine the cardiac metabolic and functional 276 
phenotype of the CP mouse, in comparison with the WT. 277 
 278 
General hematological and biochemical characteristics of the CP mouse model. Body mass, 279 
basic hematology and plasma metabolites are summarized in Table 1. Polycythemia in 280 
the CP mice was confirmed by demonstrating a modest increase in both hemoglobin and 281 
hematocrit, consistent with previous reports(18, 19, 64). No differences were seen in 282 
non-fasting plasma metabolites. 283 
 284 
CP mice have normal cardiac metabolic gene expression. The whole-heart expression of 285 
key cardiac metabolic genes revealed no differences between WT and CP mice (Figure 286 
1). In order to confirm the methodology, the expression of lung endothelin-1 was 287 
studied and found to be significantly increased in the CP mice, in keeping with previous 288 
findings(19). The full micro-array results are included in the supplemental material. 289 
 290 
CP mice exhibit features of pulmonary hypertension. Cardiac function and mass in WT and 291 
CP mice at different ages are shown in Figure 2. A full table of cine MRI results is 292 
included in Table 2. 293 
 294 
RV free wall hypertrophy, a typical feature of pulmonary hypertension, was seen in all 295 
age groups in the CP mice (Figure 2B). These findings were comparable with those 296 
reported in a previous study, in which pulmonary artery pressure and RV free wall 297 
thickness were measured using invasive techniques (19). In addition, marked 298 
interventricular septal bowing, another characteristic feature of pulmonary 299 
hypertension, was seen in all age groups in the CP mice (Figure 2F). The degree of septal 300 
bowing was quantified and is included in Table 2. 301 
 302 
In contrast to the marked changes in the RV, no differences were seen in LV mass or 303 
cardiac output (corrected for body mass; Figures 2A and C). Interestingly, LV ejection 304 
fraction was significantly increased in the younger CP mice, perhaps as a result of the 305 
pulmonary hypertension (Figure 2D). 306 
 307 
CP hearts exhibit more marked depletion of phosphocreatine under conditions of high 308 
workload. 31P MR spectroscopy of Langendorff-perfused hearts enabled the 309 
measurement of cardiac energetics under conditions of both normal and high workload. 310 
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Although cardiac energetics were similar in WT and CP hearts perfused under normal 311 
conditions, an infusion of isoproterenol (causing an approximate doubling in RPP) 312 
resulted in significantly lower PCr:ATP ratios in the CP hearts compared with WT 313 
controls (PCr:ATP 1.21 ± 0.08 in CP versus 1.56 ± 0.08, p < 0.02) (Figure 3). 314 
 315 
Glycolytic flux and lactate efflux are increased in the CP heart. Glycolytic flux in the 316 
perfused heart, measured using 3H-glucose, was 1.8-fold higher in the CP heart 317 
compared with WT controls (Figure 4A). Analysis of variance, using genotype (CP or 318 
WT) as the fixed factor and heart mass and RPP as co-variates, demonstrated that the CP 319 
mutation was the only significant determining factor on glycolytic rate (p = 0.004 for 320 
genotype; p = 0.095 for heart weight; p = 0.147 for RPP). Similarly, net lactate efflux was 321 
1.5-fold higher in the CP hearts (p = 0.009 for genotype; p = 0.121 for heart weight; p = 322 
0.123 for RPP) (Figure 4B). There was a significant correlation between glycolytic and 323 
lactate efflux rates (Pearson R = 0.935, p < 0.0001). In contrast to the increased glucose 324 
utilization and lactate production by the CP hearts, a decrease in fatty acid oxidation (as 325 
might be predicted by the Randle Cycle(27)) was undetectable (Figure 4C). 326 
 327 
In vivo pyruvate metabolism, measured in real-time, is significantly altered in the CP heart. 328 
The advent of dynamic nuclear polarization (DNP) has enabled the study of cardiac 329 
metabolism in real-time(59). In vivo 13C MR spectroscopy of hyperpolarized 13C1 330 
pyruvate revealed, in keeping with the perfusion studies, a 2-fold increase in the rate of 331 
13C1 label incorporation into lactate in the CP hearts (p < 0.01, Figure 5). Furthermore, 332 
there was a 1.6-fold increase in the rate of label incorporation into bicarbonate (p < 333 
0.05), indicating elevated flux through pyruvate dehydrogenase (Figure 5). 334 
  335 
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Discussion 336 
 337 
It is now known that HIF functions as a global master regulator, coordinating diverse 338 
cellular and systemic responses to hypoxia. Studies on patients and mice have 339 
demonstrated that perturbations in the HIF pathway, such as Chuvash polycythemia or 340 
HIF-2α gain-of-function mutations, result in profound abnormalities in systemic and 341 
cellular processes that are usually under tight control. Marked changes in skeletal 342 
muscle metabolism, ventilation, pulmonary vascular tone, and glucose homeostasis are 343 
all observed in both humans and animals with disorders of the HIF pathway(2, 13-16, 344 
18, 19, 37, 39, 46, 48, 50-53, 57, 64-66, 68, 69). We now demonstrate that chronic, 345 
modest upregulation of HIF due to the Chuvash VHL mutation results in altered cardiac 346 
metabolism and energetics in the mouse heart. 347 
 348 
A primordial function of HIF-1 is to find the optimal balance between oxidative and 349 
glycolytic metabolism for a given local oxygen concentration. As such, HIF-1 target 350 
genes, including glucose transporters and glycolytic enzymes(30, 60), lactate 351 
dehydrogenase (LDH)(61) and pyruvate dehydrogenase kinase 1 (PDK-1)(33, 47), 352 
enable increased glucose metabolism. In both hypoxia and hypoxia-mimetic models, 353 
myocardial expression of the master regulator of fatty acid metabolism, peroxisome 354 
proliferator-activated receptor α (PPARα), is decreased together with its downstream 355 
targets such as PDK-4(1, 55, 62). Alterations in cardiac mitochondrial oxidative 356 
metabolism are also seen(17). Thus, one would predict that exposure to hypoxia, or 357 
chronic activation of the HIF pathway, would result in an increased reliance upon 358 
glycolysis and glucose oxidation, and a shift away from fatty acid beta-oxidation. 359 
 360 
Most studies investigating the role of HIF in cardiac metabolism and function have 361 
employed tactics either to over-express HIF itself, or to impair its degradation by using 362 
altered levels of PHDs or VHL. Mice with cardiomyocyte-specific loss of VHL have 363 
elevated HIF levels in the heart, accompanied by increased expression of glycolytic 364 
genes, cellular lipid accumulation, and progressive heart failure(35). Combined cardiac-365 
specific loss of both PHD2 and PHD3 results in increased expression of 366 
phosphoglycerate kinase (PGK), decreased expression of PPARα, myocyte accumulation 367 
of lipid, and severe cardiomyopathy(41). Conditional somatic inactivation of PHDs 368 
produces similar results(40). Inducible cardiac-specific overexpression of an oxygen-369 
stable form of HIF-1α results in increased transcript levels of glycolytic genes and 370 
progressively impaired cardiac function(7). Furthermore, long-term constitutive 371 
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overexpression of HIF-1α results in increased glucose uptake and the development of 372 
cardiomyopathy(24). Taken together, these studies have shown that very high levels of 373 
HIF in the heart result in a switch in gene expression towards increased glucose 374 
metabolism, with accompanying contractile dysfunction. In contrast, shorter-term 375 
constitutive overexpression of HIF-1α mRNA in cardiomyocytes did not result in 376 
cardiomyopathy, but this construct only produced a barely detectable increase in HIF in 377 
normoxia. Interestingly, this overexpression was protective during myocardial 378 
infarction, where hypoxia would be expected to be present (32). 379 
 380 
Our study investigated the cardiac effects of the Chuvash VHL mutation in mice, which 381 
results in systemic, long-term, modest upregulation of HIF. Our model faithfully 382 
recapitulated findings seen in previous studies on CP patients and mice – raised 383 
hemoglobin and hematocrit, pulmonary hypertension (shown using non-invasive MRI), 384 
and RV hypertrophy (using MRI, rather than histology). However, a surprising feature of 385 
our study was the apparent lack of change in the expression of key metabolic genes 386 
within the heart, despite clear alterations in substrate metabolism and energetics. It is 387 
possible that our whole-heart analysis masked differential changes that could have been 388 
seen in the left, versus the right, ventricle(1, 62). Alternatively, the presence of 389 
pulmonary hypertension and right ventricular hypertrophy may have resulted in 390 
genetic remodeling in addition to that caused by the Chuvash VHL mutation. Finally, it is 391 
possible that the LV in the CP mouse is exposed to a chronic increase in local and/or 392 
systemic sympathetic drive(9, 10, 38, 67), which may also alter gene transcription on 393 
the background of that caused by the HIF upregulation itself. 394 
 395 
Previous studies of HIF manipulation within the mouse heart have demonstrated an 396 
increased reliance upon glucose metabolism, with accompanying contractile 397 
dysfunction(7, 24, 35, 40, 41). In the much more modest perturbation of the HIF system 398 
in the current study these two features were not coupled, in keeping with a previous 399 
study demonstrating that short-term HIF mRNA overexpression could be cardio-400 
protective(32). While there was clear evidence of increased glucose utilization and 401 
altered energetics, LV function was enhanced rather than diminished. It is likely that this 402 
increased ejection fraction is a reflection of the pulmonary hypertension demonstrated 403 
in the CP mice. One potential mechanism is that bowing of the interventricular septum 404 
arises as a consequence of the elevated pulmonary arterial pressure, and this could 405 
result directly in a reduced LV end-systolic volume. Another possible mechanism is that 406 
there is an overall increased sympathetic drive to the heart in order to maintain the 407 
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cardiac output in the face of an elevated pulmonary vascular resistance. Again, this 408 
would be expected to result in a reduced LV end-systolic volume. It should also be noted 409 
that cell types other than cardiomyocytes may be relevant. For example, endothelial cell-410 
specific HIF has been shown to influence cardiac glucose uptake, and this would have 411 
effects both in vivo and on the isolated perfused-heart preparation (26). 412 
 413 
The balance between myocardial glucose and fatty acid metabolism can be studied using 414 
the combination of radiolabelled substrates and the isolated perfused-heart(6, 8). We 415 
have demonstrated that the hearts from CP mice have elevated glycolytic flux, 416 
accompanied by increased net lactate efflux. This finding is in keeping with previous 417 
genetic studies which have shown that long-term, constitutive over-expression of HIF-418 
1α in the heart results in increased glucose uptake(24), and that cardiac-specific loss of 419 
HIF-1α causes decreased cardiomyocyte lactate concentrations(25). In our study, the 420 
increase in glycolytic flux was greater than that of PDH flux, meaning that the decrease 421 
in palmitate oxidation did not reach significance.  However, following hypoxia, mouse 422 
hearts have been shown to have increased glycolytic flux, increased lactate production 423 
and significantly decreased fatty acid oxidation (11). 424 
 425 
The advent of DNP enables flux through metabolic pathways to be measured in real-426 
time, in vivo. This technique has recently been optimized for use in small animals, such 427 
as mice, allowing genetic models to be studied for the first time(5, 12). The increased 428 
sensitivity (greater than 10, 000-fold(3)) of DNP allows the acquisition of data within 429 
one minute after infusion of a bolus of hyperpolarized 13C1 pyruvate. This bolus is 430 
required to be relatively large, however during the short time-frame of data acquisition 431 
no perturbation of plasma metabolites (other than pyruvate) or pyruvate 432 
dehydrogenase (PDH) activity occurs(4, 5). Using hyperpolarized 13C1 pyruvate MR 433 
spectroscopy, we have shown that there is increased rate of label incorporation from 434 
pyruvate into both lactate (via LDH) and bicarbonate (via PDH). By using a combination 435 
of techniques, we have therefore demonstrated that the measurements of metabolic flux 436 
obtained ex vivo are in agreement with those made in real-time in vivo. 437 
 438 
Metabolic flexibility is required for the heart to continue to perform under conditions of 439 
varying workload. Inflexibility, due to increased reliance upon a substrate such as 440 
glucose (which yields less ATP per molecule, in comparison with fatty acids) may result 441 
in myocardial energy depletion. In agreement with this hypothesis, we have 442 
demonstrated that myocardial energetics, quantified by measurement of PCr and ATP, 443 
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are reduced in the CP perfused heart under conditions of increased workload. Altered 444 
cardiac energetics are a feature of both heart failure(45) and hypoxia(20, 22, 23); our 445 
study adds to this body of evidence by demonstrating that modest long-term 446 
upregulation of HIF may result in a similar finding. 447 
 448 
In summary, a modest systemic dysregulation of the HIF pathway, caused by the 449 
Chuvash VHL mutation, resulted in clear alterations in cardiac metabolism and 450 
energetics. However, in contrast to studies generating high levels of HIF in the heart, the 451 
CP mice showed neither the predicted changes in gene expression nor any degree of LV 452 
impairment. We conclude that the effects of manipulating HIF on the heart are dose-453 
dependent. In the present study, the pulmonary hypertension associated with CP clearly 454 
had a significant effect on cardiac function. In future studies employing the CP mutation 455 
to study modest HIF dysregulation, targeting this mutation specifically to cardiac 456 
myocytes could obviate the influence of pulmonary hypertension. 457 
  458 
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Figure Captions 470 
 471 
Figure 1. Cardiac and lung gene expression. Quantitative real-time PCR was used to 472 
measure expression of key metabolic genes in hearts from WT (n = 9) and CP (n = 7) 473 
mice, aged 6 – 7 months. To confirm the methodology, expression of endothelin 1 (Edn 474 
1; dark gray) was also determined in lungs from thirteen WT and eleven CP mice. Values 475 
are mean ± 95% confidence interval. VEGF (vascular endothelial growth factor); GLUT 476 
(glucose transporter); PFKM (phosphofructokinase); PDK (pyruvate dehydrogenase 477 
kinase); LDHA (lactate dehydrogenase A); PKM (pyruvate kinase muscle); PPARa 478 
(peroxisome proliferator-activated receptor α); Edn 1 (endothelin 1). **** (p < 0.001). 479 
 480 
 481 
Figure 2. In vivo cardiac function. In vivo cine magnetic resonance imaging was used 482 
to measure cardiac mass and function in aging WT and CP mice (n = 3 – 8 mice per 483 
group). White columns (WT); black columns (CP). (A) Left ventricle (LV) mass; (B) Right 484 
ventricle (RV) wall thickness; (C) LV cardiac output, corrected to body mass; (D) LV 485 
ejection fraction. WT mice had normal cardiac morphology (E. Representative image of 486 
mouse aged 3 – 6 months). CP mice demonstrated marked interventricular septal 487 
bowing, particularly in early-diastole (F; arrows. Representative image of mouse aged 3 488 
– 6 months). * (p < 0.05); ** (p < 0.02); *** (p < 0.01). 489 
 490 
 491 
Figure 3. Perfused-heart energetics. 31P magnetic resonance spectroscopy was 492 
performed on perfused hearts from WT and CP mice (n = 5 in each group), aged 6 – 7 493 
months. Body mass 30.1 ± 2.1 g for WT, vs 28.7 ± 1.2 for CP (not significant). White 494 
columns (WT); black columns (CP). Hearts were perfused under normal Langendorff 495 
conditions using palmitate buffer and spectra were acquired, both without and with an 496 
infusion of isoproterenol in order to increase the rate pressure product. As expected, 497 
isoproterenol significantly increased the rate pressure product (p < 0.001) and 498 
decreased the PCR/ATP ratio (p < 0.001). No significant difference between WT and CP 499 
was detected without isoproterenol, but following the increase in RPP the PCr:ATP ratio 500 
was significantly lower in the CP hearts compared with WT controls. (A) rate pressure 501 
product; (B) PCr:ATP ratio. ** (p < 0.02). 502 
 503 
 504 
 505 
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Figure 4. Perfused heart metabolism. Glycolytic flux (A) and net lactate efflux (B) 506 
were determined in WT (n = 4) and CP (n = 7) mice, aged 15 – 17 months. Body mass 507 
33.8 ± 1.8 g for WT vs 29.4 ± 1.6 for CP (not significant). Glycolytic and lactate rates 508 
were highly correlated (Pearson R = 0.935, p < 0.001). Palmitate oxidation rates (C) 509 
were determined in separate mice (n = 5 in each group), aged 11 – 17 months. Body 510 
mass 27.4 ± 1.5 g for WT vs 26.2 ± 2.0 for CP (p = 0.034).  *** (p < 0.01). 511 
 512 
 513 
Figure 5. In vivo real-time cardiac metabolism. In vivo magnetic resonance 514 
spectroscopy of hyperpolarized 13C1 pyruvate was performed in WT (n = 5) and CP (n = 515 
4) mice, aged 9 – 15 months. Body mass 32.0 ± 3.0 g for WT, vs 27.0 ± 3.0 for CP (not 516 
significant). This technique allowed real-time measurement of the rate of label 517 
incorporation from pyruvate into alanine (A), bicarbonate (B), or lactate (C). * (p < 518 
0.05); *** (p < 0.01). 519 
 520 
 521 
  522 
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Tables 523 
 524 
 Wild type (n) Chuvash (n) p value 
Body mass (male mice, g) 35.9 ± 0.7 (12) 28.4 ± 0.4 (12) < 0.001 
Body mass (female mice, g) 25.3 ± 0.3 (4) 23.4 ± 0.5 (8) 0.016 
Hematocrit (%) 43 ± 0.6 (13) 51 ± 1.0 (13) < 0.001 
Hemoglobin (g L-1) 138 ± 3 (16) 158 ± 4 (13) < 0.001 
Glucose (mmol/L) 13.4 ± 1.0 (7) 13.4 ± 0.5 (7) 0.96 
Hydroxybutyrate (mmol/L) 0.18 ± 0.04 (8) 0.21 ± 0.06 (7) 0.65 
Non-esterified fatty acid 
(mmol/L) 
0.15 ± 0.01 (8) 0.13 ± 0.02 (7) 0.33 
Triacyl glycerol (mmol/L) 2.5 ± 0.2 (7) 2.2 ± 0.5 (7) 0.56 
Cholesterol (mmol/L) 1.7 ± 0.20 (8) 1.6 ± 0.05 (7) 0.44 
  525 
Table 1. Basic hematological and other parameters. Hematological values, non-526 
fasting plasma metabolites, and body masses of mice aged 6 – 7 months are shown. 527 
Results are mean  ±  SEM; the number of mice used (n) is shown in parentheses. 528 
  529 
Chuvash polycythemia and cardiac metabolism and function 
 20
 530 
  Wild type (n) Chuvash (n) p value 
Body mass (grams) 3 months 28 ± 1.8 (4) 24 ± 1.3 (7) 0.093 
 6 months 36 ± 1.1 (4) 25 ± 1.2 (9) < 0.0001 
 12 months 37 ± 3.2 (5) 27 ± 0.9 (8) 0.003 
LV ejection fraction (%) 3 months 61.5 ± 3.7 (3) 71.5 ± 2.2 (6) 0.043 
 6 months 54.0 ± 1.7 (4) 68.4 ± 3.2 (8) 0.014 
 12 months 55.5 ± 5.6 (5) 66.5 ± 2.9 (8) 0.078 
LV mass (% of body mass) 3 months 0.42 ± 0.01 (3) 0.39 ± 0.02 (6) 0.262 
 6 months 0.37 ± 0.04 (5) 0.39 ± 0.01 (7) 0.584 
 12 months 0.38 ± 0.04 (5) 0.38 ± 0.02 (8) 0.952 
MV RV wall thickness (mm) 3 months 0.35 ± 0.02 (3) 0.47 ± 0.03 (7) 0.021 
 6 months 0.34 ± 0.02 (5) 0.45 ± 0.02 (8) 0.001 
 12 months 0.35 ± 0.02 (5) 0.51 ± 0.02 (7) 0.001 
Septal bowing ratio 3 months 0.91 ± 0.009 (3) 0.83 ± 0.03 (7) 0.038 
 6 months 0.92 ± 0.004 (5) 0.80 ± 0.01 (7) < 0.0001 
 12 months 0.93 ± 0.0 (4) 0.83 ± 0.01 (7) < 0.0001 
Heart rate (beats per min) 3 months 420 ± 29 (3) 373 ± 8 (6) 0.069 
 6 months 413 ± 10 (5) 398 ± 3 (8) 0.202 
 12 months 418 ± 3 (5) 402 ± 7 (8) 0.129 
Stroke volume (ml) 3 months 35.1 ± 2.9 (3) 32.2 ± 1.2 (7) 0.282 
 6 months 34.5 ± 1.0 (5) 30.8 ± 2.3 (8) 0.24 
 12 months 37.1 ± 1.5 (4) 28.1 ± 1.4 (8) 0.003 
Cardiac output (ml/min) 3 months 14.8 ± 2.0 (3) 12.5 ± 0.8 (7) 0.226 
 6 months 14.3 ± 0.5 (5) 12.2 ± 0.9 (8) 0.116 
 12 months 14.6 ± 1.2 (5) 11.3 ± 0.7 (8) 0.025 
LV Cardiac index (ml/min/g) 3 months 0.54 ± 0.03 (3) 0.52 ± 0.03 (7) 0.756 
 6 months 0.43 ± 0.03 (5) 0.48 ± 0.03 (8) 0.197 
 12 months 0.40 ± 0.01 (5) 0.43 ± 0.02 (8) 0.322 
  531 
Table 2. Full cine MRI data. Results are mean  ±  SEM; the number of mice used (n) is 532 
shown in parentheses. For the ‘Septal bowing ratio’, the greater the distortion of the LV 533 
by the septum, the greater the deviation from the perfect circle ratio of 1.0. 534 
  535 
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